Peloton Interactive Inc shares are trading lower after the company reported worse-than-expected first-quarter EPS and sales results. The stock may also be seeing added pressure following positive data from Pfizer for its COVID-19 oral antiviral treatment candidate. Peloton is widely considered a stay-at-home play during the ongoing COVID-19 pandemic.
See Also: Peloton Sees A Huge Drop: Here's A Closer Look At The Stock Chart
Peloton reported quarterly losses of $1.25 per share which missed the analyst consensus estimate of a loss of $1.07 by 17%. Peloton reported quarterly sales of $805.20 million which missed the analyst consensus estimate of $810.76 million by 0.7%. This is a 6% increase over sales of $757.90 million in the same period last year.
See Also: Why Pfizer Shares Are Surging Today
Several anaylsts have updated their price targets for Peloton following the first-quarter earnings release:
- Keybanc analyst Edward Yruma maintains Peloton with a Overweight and lowers the price target from $155 to $110.
- Telsey Advisory Group analyst Dana Telsey downgrades Peloton from Outperform to Market Perform and lowers the price target from $135 to $70.
- Stifel analyst Scott Devitt downgrades Pelotonfrom Buy to Hold and lowers the price target from $120 to $70.
- Truist Securities analyst Youssef Squali downgrades Peloton from Buy to Hold and lowers the price target from $130 to $68.
- Exane BNP Paribas analyst Laurent Vasilescu downgrades Peloton from Outperform to Neutral and announces $89 price target.
- Needham analyst Bernie McTernan maintains Peloton with a Buy and lowers the price target from $130 to $105.
- Credit Suisse analyst Kaumil Gajrawala maintains Peloton with a Outperform and lowers the price target from $148 to $112.
Peloton provides interactive fitness products in North America and internationally. It offers connected fitness products with touchscreen that streams live and on-demand classes under the Peloton Bike, Peloton Bike+, Peloton Tread and Peloton Tread+ names.
Peloton has a 52-week high of $171.09 and a 52-week low of $80.48.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.